Moreover, stratifying prostate cancer cases according to the ADT regimen utilized for treatment revealed that PTEN expression status (PTEN loss vs. intact PTEN) had no significant effect on mean time-to-resistance in patients receiving goserelin only (p=0.19), triptorelin only (p=0.13), bicalutamide only (p=069), or combination/sequential ADT (p=0.87), as shown in Table 3. The gene discussed is PTEN; the disease is prostate cancer.